Image

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

Recruiting
21 years and younger
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction [AVDSf]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS).

The study aims are:

  1. To validate AVDSf for risk stratification of mortality in pediatric ARDS
  2. To determine if there is heterogeneity in treatment effect for iNO defined by AVDSf
  3. To detect the association between AVDSf and microvascular dysfunction trajectory and whether iNO therapy modifies this association

This is a prospective, multicenter observational study of 1260 mechanically ventilated children with moderate to severe ARDS. In a subgroup of 450 children with severe ARDS, longitudinal blood samples will be obtained to measure plasma protein markers.

Eligibility

Inclusion Criteria:

  • Age >37 weeks corrected gestational age to 21 years, including adults lacking the capacity to consent.
  • Within 72 hours of the start of invasive mechanical ventilation and meet the criteria for pediatric ARDS (new infiltrate on chest imaging and a known ARDS risk factor within 7 days of the onset of hypoxemia) and either meet criteria for moderate or severe pediatric ARDS between 4-72 hours of IMV (OI ≥ 8 or OSI ≥ 7.5) OR have an OI ≥ 20 or an OSI ≥ 14 x 15 minutes between 0-4 hours of IMV.
  • Subgroup of children eligible for longituduinal Blood Collection: Children with severe PARDS (OI ≥ 16 or an OSI ≥ 12 between 4-72 hours of IMV) or those with an OI ≥ 20 or an OSI ≥ 14 for 15 minutes between 0-4 hours of IMV will be eligible for collection of longitudinal plasma samples.

Exclusion Criteria:

  • Non-conventional invasive mechanical ventilation (i.e. High Frequency Oscillatory Ventilation, Airway Pressure Release Ventilation) at the time of ICU admission
  • ECMO or iNO (or other inhaled pulmonary vasodilator therapy) at the time of ICU admission
  • Significant lower airways obstruction (examination of ventilator and capnography waveforms by site study or medical team)
  • Air leak >20% (endotracheal tube, tracheostomy tube, or thoracostomy tube)
  • Home Invasive Mechanical Ventilation
  • Cyanotic Congenital Heart Disease
  • Previous enrollment in the DiNO study
  • Do not resuscitate order at the time of pediatric ARDS diagnosis.
  • Blood gas not obtained prior to initiation of ECMO, iNO, or non-conventional ventilation.

Study details
    Acute Respiratory Distress Syndrome

NCT06690801

Children's Hospital Los Angeles

16 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.